ResMed Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared primarily with FY2022. The request metadata says “2022 Q4,” but the filing is an FY2023 Form 10-K; the filing separately reports FY2023 fourth-quarter results.
Business context
ResMed designs and sells sleep and respiratory care devices, masks, diagnostics and connected health solutions, and provides software as a service (SaaS) to out-of-hospital care providers. It reports two segments: Sleep and Respiratory Care and SaaS. Products are sold in more than 140 countries.
Financial and operating performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $4.223 billion | $3.578 billion | +18% reported; +21% constant currency |
| Gross profit | $2.356 billion | $2.024 billion | +16% |
| Gross margin | 55.8% | 56.6% | Down 0.8 percentage points |
| Operating income | $1.132 billion | $1.000 billion | +13% |
| Net income | $897.6 million | $779.4 million | +15% |
| Diluted EPS | $6.09 | $5.30 | +15% |
| Operating cash flow | $693.3 million | $351.1 million | +$342.2 million |
Sleep and Respiratory Care revenue was $3.725 billion, up 17% (20% constant currency); device revenue rose 22% and masks and other revenue rose 11%. SaaS revenue was $498.0 million, up 24%, largely reflecting the MEDIFOX DAN acquisition; excluding that acquisition, SaaS revenue increased 8%.
FY2023 fourth-quarter revenue was $1.122 billion versus $914.7 million a year earlier; net income was $229.7 million versus $195.1 million, and diluted EPS was $1.56 versus $1.33.
Cash and cash equivalents were $227.9 million at year-end, down from $273.7 million. Working capital was $1.609 billion. Total debt was approximately $1.441 billion, versus $775.2 million a year earlier; $745.0 million remained available under the revolving credit facility. Management said existing liquidity should fund operations and expected capital expenditures for the next 12 months and beyond.
Changes, drivers and unusual items
- Revenue growth reflected higher device demand, reduced competitive supply, higher average selling prices and sales of card-to-cloud products, as well as mask unit growth. Foreign currency movements reduced Sleep and Respiratory Care revenue by approximately $95.6 million.
- Gross margin declined amid product mix, component and manufacturing costs, warehouse costs and foreign exchange, partly offset by pricing and lower acquired-intangible amortization.
- Cash from operations increased in part because FY2022 included a $284.8 million payment to settle the Australian Taxation Office dispute, as well as higher FY2023 operating profit.
- Investing cash outflow was $1.160 billion, principally reflecting the MEDIFOX DAN acquisition. ResMed acquired the German software provider in November 2022 for approximately $997.5 million, funded with revolving-credit borrowings.
- FY2023 included a $20.2 million gain on business-interruption insurance recoveries and $9.2 million in restructuring expenses, primarily employee severance. The company paid $258.3 million in dividends and declared a subsequent quarterly dividend of $0.48 per share.
Outlook, risks and contingencies
The filing does not provide numerical revenue or earnings guidance. Management describes continued investment in product development, digital health and SaaS, and expects its platforms and product pipeline to support growth. It also states that supply constraints, working-capital needs and capital deployment can cause cash flows to fluctuate.
- Supply constraints in raw materials and electronic components, including semiconductors, may limit production and raise costs. Single-source suppliers and the availability of communications modules are additional exposures.
- Philips’ product recall reduced competitive supply; a return of its products to the market could affect ResMed demand. Competitive pressure, pricing and healthcare-provider consolidation may also affect sales and margins.
- Reimbursement reductions, healthcare reform and changing clinical or coverage assessments could pressure customer demand and product pricing.
- Foreign exchange, inflation, interest rates, geopolitical events and international trade restrictions may affect costs, revenue and supply continuity.
- Cybersecurity, privacy and service-continuity risks are material considerations for a business with connected devices and cloud software. Medical-device regulation, quality requirements and data-protection laws create compliance and execution risks.
- ResMed disclosed patent litigation involving New York University and Cleveland Medical. The NYU case was stayed pending patent-review proceedings; the Cleveland Medical Delaware case was set for trial in August 2024. The company said it could not reasonably estimate losses, if any, on open matters, while stating that ordinary-course proceedings were not expected to materially affect the consolidated financial statements as a whole.
- The company reported $1.391 billion of purchase obligations, largely due within FY2024 and FY2025. Its total debt had variable-rate exposure, although management said a hypothetical 10% interest-rate change would not have materially affected pretax income.
Important facts for investors to verify
- Confirm the intended period: this filing covers FY2023, not a standalone 2022 Q4 filing; use the reported quarterly table for Q4 comparisons.
- Assess whether FY2023 revenue growth and device demand are sustainable if competitors restore supply, and distinguish acquisition-driven SaaS growth from organic growth.
- Track gross-margin recovery against component, manufacturing, logistics and foreign-exchange costs.
- Review inventory growth, cash conversion, purchase commitments and debt repayment capacity following the MEDIFOX DAN acquisition.
- Monitor the status and potential financial impact of the disclosed patent cases, as well as reimbursement and regulatory developments.
- Consider the FY2023 insurance recovery and acquisition-related items when evaluating underlying earnings; review GAAP results alongside management’s non-GAAP measures and their adjustments.
KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. The internal-control assessment excluded MEDIFOX DAN while it was being integrated.